Publication

Article

CURE

Winter 2007
Volume6
Issue 6

Blood Counts May Predict Survival

Blood counts predict leukemia survival and relapse.

Survival rates for children and young adults with acute lymphocytic leukemia (ALL) average 80 percent, and acute myeloid leukemia (AML) survival rates reach an average of only 40 percent. Now, doctors hope a simple blood test that measures absolute lymphocyte counts (ALC) will help predict survival after five years and the risk of relapse. This information could help doctors determine how aggressively to treat a patient.

According to a Cancer study published online in November, patients with low ALC—the measure of normal immune cells—at two weeks after the initial chemotherapy did not do as well as patients with high ALC. Study investigators examined 10 years of data from 171 newly diagnosed ALL and AML patients under age 21. The six-year survival rate for ALL patients with high lymphocyte counts was 87 percent, while a low count equated to 55 percent survival. In AML patients, five-year survival was 85 percent with a high count, and 28 percent with a low count.

While malignant white blood cells have long been known to influence outcome, Patrick Zweidler- McKay, MD, PhD, co-author of the study, says experts in the field first couldn’t believe normal lymphocytes could have this particular predictive ability. “I agree with the people who say it’s too easy, that it’s been right in front of our noses. But, on the other hand, I can’t ignore the fact that it’s there,” says Dr. Zweidler-McKay, an assistant professor at the Children’s Cancer Hospital at M.D. Anderson Cancer Center in Houston.

And the predictability doesn’t just apply to childhood leukemia. Dr. Zweidler-McKay says other studies have demonstrated the technique’s success in T-cell and follicular lymphomas and Ewing’s sarcoma. “This story is just building and building,” he says. “Every population they’ve looked at, there has been a correlation.

Now the important question is how to use the test and what to do if a patient’s counts are low. “I’d like to really start making decisions based upon it,” Dr. Zweidler-McKay says. “If you have a predictive ability that’s stronger than anything that’s out there ... it’s on [doctors] to do something about it.”

Related Videos
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.